Please assess the completion status of the following clinical trial:

Trial Title: Uric Acid in Essential Hypertension in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Males or females 12 to 18 years in age.~SBP or DBP greater than 95th percentile for age, gender and height~Diagnosis of primary hypertension after initial workup~No pharmacological therapy for hypertension in the past 12 months~Females must have a negative urine pregnancy test.~Parental or guardian consent and child subject assent~Exclusion Criteria:~Severe or poorly controlled hypertension as defined by SBP or DBP more than 20mmHg \>95th percentile for age, gender and height or a history of hypertensive encephalopathy~Identified cause of secondary hypertension Renal transplant~Taking a calcineurin inhibitor, azathioprine or another nucleoside analogue medication (These medications have potentially serious drug interactions with Allopurinol.)~Currently receiving antihypertensive medication(s) or diuretic(s)~Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary or renal disease (These abnormalities would be expected to alter drug metabolism and increase the likelihood of medication side effects.):~Schwartz Formula GFR less than 60ml/min/1.73m2, AST/SGOT greater than 2 times the upper limit of normal\* ALT/SGPT greater than 2 times the upper limit of normal\* Total or direct bilirubin more than 2 times the upper limit of normal\* Hemoglobin less than 9 gm/dl WBC less than 3.000/mm3 Platelet count less than 100,000/mm3 \*age-adjusted normal range

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol (Type: EXPERIMENTAL): Hypertensive children received both placebo and allopurinol in a cross over design.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).